Navigation Links
Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals
Date:7/21/2011

RIDGEFIELD, Conn., July 21, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has been added to hospital formularies at 49 of the top 50 cardiology and heart surgery hospitals, as ranked by U.S. News & World Report's Best Hospitals 2011-2012, published online on July 19.  PRADAXA is approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).(1)

Atrial fibrillation (AFib), characterized by an irregular heartbeat,(2) increases the risk of stroke nearly five times.(3)  Approximately 80 percent of U.S. adults living with AFib are age 65 or older,(4) and many have other conditions, such as diabetes or hypertension, that further increase the risk of stroke.(2)  A Medicare claims database analysis showed that approximately 70 percent of NVAF patients are hospitalized each year.(5) Overall, annual hospital admissions for NVAF, as a primary or secondary diagnosis, total nearly 2.7 million or approximately seven percent of all hospital admissions in the U.S.(6)  

"At Boehringer Ingelheim, patients are our first priority and we've worked with hospitals across the country to support the addition of PRADAXA to formularies," said Wa'el Hashad, vice president, cardiovascular and metabolic disorders marketing, Boehringer Ingelheim Pharmaceuticals, Inc. "In the first seven months after approval, more than 250,000 patients were prescribed PRADAXA, suggesting this important treatment has been well received in the everyday clinical setting to reduce the risk of stroke in patients with non-valvular atrial fibrillation."

PRADAXA is now included on formularies that insure about 90 percent of covered lives in the U.S.(7)  For those patients who may not otherwise be able to afford treatment, BIPI offers patient assista
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)
2. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
3. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
4. Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
5. Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
6. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
7. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
8. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
9. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
10. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
11. Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500mg Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ... estimates and forecasts of the revenue and share ...
(Date:12/24/2014)... York (PRWEB) December 23, 2014 According to ... Long Island Affiliate of ITRA Global, the national office market ... steady recovery. This is evidenced by the third quarter’s ... stock market. Low energy costs have held inflation down ... only negative is the housing market remaining soft. , This ...
(Date:12/24/2014)... BEIJING , Dec. 23, 2014 ... or the "Company"), a leading fully integrated plasma-based ... today announced that its majority-owned subsidiary, Shandong Taibang ... Practices ("GMP") certification from the China Food and ... factor production facility. As previously disclosed in the ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  NeuroLifeSciences ... of mazindol in children with attention deficit/hyperactivity disorder published ... 2014 . The paper, titled "Pilot ... deficit/hyperactivity disorder" ( Konofal et al, Drug ... 2014 ) shows that mazindol might be an ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... Milwaukee-based provider of financial technology solutions selected Opsware ... operations Tuesday. Metavante plans to use Opsware to automate ... center information technology environment. , ,We selected Opsware ... complexity and cost in the data center, said Brian ...
... and be more responsive to the needs of their ... they provide as a result of two new products ... company. API Software announced Tuesday the availability of the ... scheduling application, which recently acquired two new contracts. ...
... Third Wave Technologies Inc. , a Madison-based provider of ... 2003 last Tuesday. The year was transitional for Third ... financial resources away from the genomic tools market and ... revenue of $36.3 million and a net loss of ...
Cached Biology Technology:API Releases New Software, Acquires Additional Contracts 2
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the addition of the "The Global ... their offering. ... an overview of the global digital media ... control and monitor piracy by securely and ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... July 2012, Apple introduced the fingerprint reading feature ... only device of Apple incorporating such a feature, ...
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Ann Liebert, Inc. is pleased to announce significant growth ... Impact Factors published by Thomson Reuters. More than half ... the majority achieving an increase of 10% and higher. ... editorial standards for exceptional quality, supported by outstanding review ...
... Smithsonian Conservation Biology Institute and George Mason University ... complex that embodies the concept of the living ... Studies Program has trained future conservationists with an ... Smithsonian National Zoological Park,s 3,200-acre facility in Front ...
... YORK, N.Y. (June 30, 2011) Autism Speaks Weatherstone Pre-Doctoral ... a 2010 fellow, recently published new findings in the journal ... autism. Their research is based on a mouse model that ... to be associated with autism spectrum disorder (ASD), known as ...
Cached Biology News:Smithsonian Conservation Biology Institute and George Mason University expand partnership 2Weatherstone Fellows publish research as Autism Speaks announces 2011 Weatherstone Fellows 2Weatherstone Fellows publish research as Autism Speaks announces 2011 Weatherstone Fellows 3
... Neogens enzyme-linked immunosorbent assay (ELISA) test ... screening devices for the detection of drugs ... kits are intended for forensic use only. ... be confirmed by a quantitative method such ...
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... pending) is a protein based inhibitor of ... the most common and troublesome RNases including ... SUPERaseIn can be used in any application ... is ideal for in vitro transcription and ...
... Inhibitor is a recombinant human protein produced in ... neutral pancreatic RNase A type enzymes. The ... binds RNases in a 1:1 ratio. The enzyme ... many tissues and cell types. Addition of the ...
Biology Products: